{"filing":{"accession_number":"0001628280-26-056497","cik":"0001636651","ticker":"OVID","company_name":"Ovid Therapeutics Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-11","primary_document":"ovid-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/ovid-20260813.htm"},"events":[{"id":27560,"run_id":25128,"accession_number":"0001628280-26-056497","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses second quarter 2026 financial results for Ovid Therapeutics, including condensed consolidated statements of operations showing revenue, operating expenses, net loss, and loss per share, along with select balance sheet data as of June 30, 2026. The press release (Exhibit 99.1) explicitly announces \"Second Quarter 2026 Financial Results\" with detailed financial metrics and comparisons to the prior year period, which is the hallmark of an earnings release under Item 2.02.","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29143,"accession_number":"0001628280-26-056497","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses second quarter 2026 financial results for Ovid Therapeutics, including condensed consolidated statements of operations showing revenue, operating expenses, net loss, and loss per share, along with select balance sheet data as of June 30, 2026. The press release (Exhibit 99.1) explicitly announces \"Second Quarter 2026 Financial Results\" with detailed financial metrics and comparisons to the prior year period, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:33:40.904217+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29143,"accession_number":"0001628280-26-056497","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses second quarter 2026 financial results for Ovid Therapeutics, including condensed consolidated statements of operations showing revenue, operating expenses, net loss, and loss per share, along with select balance sheet data as of June 30, 2026. The press release (Exhibit 99.1) explicitly announces \"Second Quarter 2026 Financial Results\" with detailed financial metrics and comparisons to the prior year period, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:33:40.904217+00:00","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-08-13"}]}